New Test Options for NTRK Gene Fusions

The presence NTRK gene fusions is one of the eligibility requirements for the recently FDA-approved therapy Vitrakvi (larotrectinib), a therapy indicated in adult and pediatric patients with solid tumors regardless of the type of tumor. NTRK gene fusions have been described in many cancers at various frequencies, including common cancers such as lung, thyroid, and colorectal cancers. 

Testing Specific for the Assessment of NTRK Gene Fusions:

Testing Designed for Specific Tumor Types:

At MCL, this testing can be performed concurrently with other tissue testing such as the gastrointestinal stromal tumor NGS panel (GISTP), colorectal RAS/RAF NGS panel (RASFP), or it can be performed as a stand-alone assay on any FFPE tumor tissue.

Alyssa Frank (@alyssafrank)

Alyssa Frank

Alyssa Frank is a Marketing Segment Manager at Mayo Clinic Laboratories. She leads marketing strategies for product management and specialty testing. Alyssa has worked at Mayo Clinic since 2015.